Tests Performed at Point of Care See Higher Revenue Growth, Investor Interest: Kalorama
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 12/13/12 -- The market for (POC) testing is demonstrating stronger-than-expected growth, according to Kalorama Information. The revised its earlier forecast and projects the $16.7 billion market will grow at 6 percent a year, slightly higher than the in vitro diagnostics market as a whole. The firm based its enhanced growth projection on the activity of more than forty new entrants in POC testing in recent years, the 2012 results of existing competitors, and the product innovations that have occurred in the market. The finding was made in its report, , authored by Sannes & Associates.
Point of care () is a broad term which describes tests purchased and used by patients themselves, such as pregnancy and cholesterol tests, as well as tests performed at physicians' offices, clinics and other patient care sites. A good portion of the market is glucose monitoring, but coagulation and can also be performed at the in some cases. in Kalorama's market analysis does not include tests sent to a central lab for processing. What makes attractive is that the results can be known in real time and on site where they can immediately influence treatment decisions.
"Growth in POC testing is being fueled by chronic diseases, the globalization of infectious diseases and the associated public health issues," the report indicated. "Advances in therapies are giving physicians more tools for the treatment of patients if they are able to rapidly diagnose the problem, which is helping to make the case for POC test purchases and investment in companies that provide them."
Forecasts for POC revenue growth are optimistic, but not as cheery as some made by the industry in the past. In the late 1990s, the POC diagnostic market was expected to grow at a rate of 15% to 20% per year. While it has grown and is now a significant segment of the overall in vitro diagnostic (IVD) market, the rapid growth rates that were originally expected have never been achieved. With the exception of blood glucose monitoring, POC testing has not significantly penetrated other segments of the IVD industry.
The field for rapid test devices is crowded. Kalorama lists 140 companies that currently market POC tests, plus more than 40 additional companies that are developing POC technologies and products and that have just recently entered this market. Companies profiled in this report are using a wide range of different technologies to develop and market rapid tests for much of the range of IVD tests that can be performed in centralized laboratories.
Kalorama's full-length study on the market for point of care testing, , contains a detailed segment breakdown of revenues, profiles of companies in the market and a discussion of trends. New POC innovations are also detailed in the report.
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on , and our .
Please direct all media inquiries to:
Bruce Carlson
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.12.2012 - 14:43 Uhr
Sprache: Deutsch
News-ID 1180302
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Hospitals, Facilities and Providers
Anmerkungen:
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Tests Performed at Point of Care See Higher Revenue Growth, Investor Interest: Kalorama
"
steht unter der journalistisch-redaktionellen Verantwortung von
Kalorama Information (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
